神経調節デバイスの世界市場規模、シェア、動向分析：製品別、用途別、最終用途別、地域別（2025年～2030年）

神経調節デバイス市場の成長と動向：

Grand View Research, Inc.の最新レポートによると、世界の神経調節デバイスの市場規模は、2030年までに103億9,000万米ドルに達し、2025年～2030年のCAGRは8.51％を記録すると予測されています。

同市場の成長は、神経疾患の有病率の上昇、研究開発に対する政府支援の増加、応用範囲の拡大を伴う先進ソリューションの開発といった要因に起因しています。

政府や民間機関からの多額の資金援助は、神経疾患の理解を進め、治療法を改善する上で重要な役割を果たしています。政府は研究イニシアチブに資源を配分することで、画期的な発見を積極的に促進し、技術革新を奨励し、より効果的な神経調節技術の開発を促進しています。例えば、パーキンソン財団は2024年8月、パーキンソン病（PD）の理解と治療の進歩を目的とした33の研究助成金に約300万米ドルを投資すると発表しました。この助成金は、PDの原因、進行、潜在的な治療法など、PDのさまざまな側面に焦点を当てた革新的な研究プロジェクトを支援します。この助成金は、患者の予後改善につながる科学的進歩を促進するという財団のコミットメントの一環です。このような財政的支援は、神経疾患の治療状況を形成し、患者の治療に前向きな変化をもたらすために不可欠です。

さらに、患者やヘルスケア専門家がこれらの先進的な機器を利用しやすくなったことで、その普及はさらに進んでいます。診療報酬の拡大により、こうした先進治療への患者のアクセスも向上しています。近年、ヘルスケアシステムは、慢性疼痛、神経疾患、その他のさまざまな病状の管理における神経調節デバイスの有効性をますます認めるようになっており、多くの医療保険者がこれらのデバイスを保険適用方針に含めるようになっています。例えば、2024年2月、米国ではハイマーク（Highmark Inc.）が、Nerivio Remote Electrical Neuromodulation（REN）ウェアラブルを非薬理学的片頭痛治療として初めて商用保険に適用しました。このウェアラブルは急性および予防的治療の選択肢を提供し、片頭痛症状の軽減に大きな臨床的効果があることを示しています。このように、支払者の間で神経調節療法が受け入れられつつあることが、市場成長の原動力となっています。

神経調節デバイス市場レポートのハイライト

• 脊髄刺激デバイスは2024年に約39.67%の最大市場シェアを占めました。脊髄刺激デバイスは主に、非外科的疼痛治療で十分な鎮痛効果が得られない患者に使用されます。
• パーキンソン病は、2024年に約26.90%の最大市場シェアを占めました。パーキンソン病の有病率の上昇と、脳深部刺激が効果的な治療オプションとして受け入れられつつあることが相まって、同セグメントの成長を促進すると予測されています。
• 病院と外来手術センター（ASC）は、2024年に最大の市場シェアを占め、予測期間中に同セグメントが最も速い成長を示すと予測されています。
• 北米の神経調節デバイス市場は、アルツハイマー病、パーキンソン病、てんかんなどの様々な神経疾患の有病率の増加、低侵襲神経学的処置の需要の増加により、2024年に43.68％のシェアを占めました。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 神経調節デバイスの変数、動向、範囲

• 市場系統の見通し
  • 親市場の見通し
  • 関連/付随市場の見通し
• 市場力学
  • 市場促進要因分析
  • 市場抑制要因分析
• 神経調節デバイス分析ツール
  • 業界分析：ポーターのファイブフォース分析
  • PESTEL分析

第4章 神経調節デバイス市場 - セグメント分析：製品別（2018年～2030年）

• 神経調節デバイス市場：製品の展望と重要なポイント
• 神経調節デバイス市場：製品の変動分析
• 製品別
• 脊髄刺激デバイス
  • 脊髄刺激デバイス市場（2018年～2030年）
• 脳深部刺激デバイス
  • 深部脳刺激デバイス市場（2018年～2030年）
• 仙骨神経刺激デバイス
  • 仙骨神経刺激デバイス市場（2018年～2030年）
• 迷走神経刺激デバイス
  • 迷走神経刺激デバイス市場（2018年～2030年）
• 胃電気刺激
  • 胃電気刺激市場（2018年～2030年）
• その他
  • その他市場（2018年～2030年）

第5章 神経調節デバイス市場 - セグメント分析：用途別（2018年～2030年）

• 神経調節デバイス市場：用途の展望と重要なポイント
• 神経調節デバイス市場：用途の変動分析
• 用途別
• パーキンソン病
  • パーキンソン病市場（2018年～2030年）
• 慢性疼痛
  • 慢性疼痛市場（2018年～2030年）
• てんかん
  • てんかん市場（2018年～2030年）
• 片頭痛
  • 片頭痛市場（2018年～2030年）
• 尿失禁および便失禁
  • 尿失禁および便失禁市場（2018年～2030年）
• 振戦
  • 振戦市場（2018年～2030年）
• うつ
  • うつ市場（2018年～2030年）
• その他
  • その他市場（2018年～2030年）

第6章 神経調節デバイス市場 - セグメント分析：最終用途別（2018年～2030年）

• 神経調節デバイス市場：最終用途の展望と重要なポイント
• 神経調節デバイス市場：最終用途の変動分析
• 最終用途別
• 病院および外来手術センター（ASC）
  • 病院および外来手術センター（ASC）市場（2018年～2030年）
• クリニックおよび理学療法センター
  • クリニックおよび理学療法センター市場（2018年～2030年）
• その他
  • その他市場（2018年～2030年）

第7章 神経調節デバイス市場：地域の推定・動向分析

• 地域ダッシュボード
• 市場規模と予測動向分析（2018年～2030年）
• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • 英国
  • ドイツ
  • フランス
  • イタリア
  • スペイン
  • ノルウェー
  • スウェーデン
  • デンマーク
• アジア太平洋
  • 日本
  • 中国
  • インド
  • オーストラリア
  • 韓国
  • タイ
• ラテンアメリカ
  • ブラジル
  • アルゼンチン
• 中東・アフリカ
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • クウェート

第8章 競合情勢

• 市場参入企業の分類
• 主要市場参入企業による最近の動向と影響分析
• 企業市場シェア分析：2024年
• 主要企業プロファイル
  • Abbott
  • Medtronic
  • Boston Scientific Corporation
  • Nexstim
  • LivaNova PLC
  • Neuropace Inc.
  • Nevro Corporation
  • electroCore, Inc.
  • Axonics, Inc.
  • Laborie

List of Tables

• Table 1 List of abbreviation
• Table 2 North America neuromodulation devices market, by region, 2018 - 2030 (USD Million)
• Table 3 North America neuromodulation devices market, by Product, 2018 - 2030 (USD Million)
• Table 4 North America neuromodulation devices market, by application, 2018 - 2030 (USD Million)
• Table 5 North America neuromodulation devices market, by end-use, 2018 - 2030 (USD Million)
• Table 6 U.S. neuromodulation devices market, by Product, 2018 - 2030 (USD Million)
• Table 7 U.S. neuromodulation devices market, by application, 2018 - 2030 (USD Million)
• Table 8 U.S. neuromodulation devices market, by end-use, 2018 - 2030 (USD Million)
• Table 9 Canada neuromodulation devices market, by Product, 2018 - 2030 (USD Million)
• Table 10 Canada neuromodulation devices market, by application, 2018 - 2030 (USD Million)
• Table 11 Canada neuromodulation devices market, by end-use, 2018 - 2030 (USD Million)
• Table 12 Mexico neuromodulation devices market, by Product, 2018 - 2030 (USD Million)
• Table 13 Mexico neuromodulation devices market, by application, 2018 - 2030 (USD Million)
• Table 14 Mexico neuromodulation devices market, by end-use, 2018 - 2030 (USD Million)
• Table 15 Europe neuromodulation devices market, by region, 2018 - 2030 (USD Million)
• Table 16 Europe neuromodulation devices market, by Product, 2018 - 2030 (USD Million)
• Table 17 Europe neuromodulation devices market, by application, 2018 - 2030 (USD Million)
• Table 18 Europe neuromodulation devices market, by end-use, 2018 - 2030 (USD Million)
• Table 19 Germany neuromodulation devices market, by Product, 2018 - 2030 (USD Million)
• Table 20 Germany neuromodulation devices market, by application, 2018 - 2030 (USD Million)
• Table 21 Germany neuromodulation devices market, by end-use, 2018 - 2030 (USD Million)
• Table 22 UK neuromodulation devices market, by Product, 2018 - 2030 (USD Million)
• Table 23 UK neuromodulation devices market, by application, 2018 - 2030 (USD Million)
• Table 24 UK neuromodulation devices market, by end-use, 2018 - 2030 (USD Million)
• Table 25 France neuromodulation devices market, by Product, 2018 - 2030 (USD Million)
• Table 26 France neuromodulation devices market, by application, 2018 - 2030 (USD Million)
• Table 27 France neuromodulation devices market, by end-use, 2018 - 2030 (USD Million)
• Table 28 Italy neuromodulation devices market, by Product, 2018 - 2030 (USD Million)
• Table 29 Italy neuromodulation devices market, by application, 2018 - 2030 (USD Million)
• Table 30 Italy neuromodulation devices market, by end-use, 2018 - 2030 (USD Million)
• Table 31 Spain neuromodulation devices market, by Product, 2018 - 2030 (USD Million)
• Table 32 Spain neuromodulation devices market, by application, 2018 - 2030 (USD Million)
• Table 33 Spain neuromodulation devices market, by end-use, 2018 - 2030 (USD Million)
• Table 34 Denmark neuromodulation devices market, by Product, 2018 - 2030 (USD Million)
• Table 35 Denmark neuromodulation devices market, by application, 2018 - 2030 (USD Million)
• Table 36 Denmark neuromodulation devices market, by end-use, 2018 - 2030 (USD Million)
• Table 37 Sweden neuromodulation devices market, by Product, 2018 - 2030 (USD Million)
• Table 38 Sweden neuromodulation devices market, by application, 2018 - 2030 (USD Million)
• Table 39 Sweden neuromodulation devices market, by end-use, 2018 - 2030 (USD Million)
• Table 40 Norway neuromodulation devices market, by Product, 2018 - 2030 (USD Million)
• Table 41 Norway neuromodulation devices market, by application, 2018 - 2030 (USD Million)
• Table 42 Norway neuromodulation devices market, by end-use, 2018 - 2030 (USD Million)
• Table 43 Asia Pacific neuromodulation devices market, by region, 2018 - 2030 (USD Million)
• Table 44 Asia Pacific neuromodulation devices market, by Product, 2018 - 2030 (USD Million)
• Table 45 Asia Pacific neuromodulation devices market, by application, 2018 - 2030 (USD Million)
• Table 46 Asia Pacific neuromodulation devices market, by end-use, 2018 - 2030 (USD Million)
• Table 47 China neuromodulation devices market, by Product, 2018 - 2030 (USD Million)
• Table 48 China neuromodulation devices market, by application, 2018 - 2030 (USD Million)
• Table 49 China neuromodulation devices market, by end-use, 2018 - 2030 (USD Million)
• Table 50 Japan neuromodulation devices market, by Product, 2018 - 2030 (USD Million)
• Table 51 Japan neuromodulation devices market, by application, 2018 - 2030 (USD Million)
• Table 52 Japan neuromodulation devices market, by end-use, 2018 - 2030 (USD Million)
• Table 53 India neuromodulation devices market, by Product, 2018 - 2030 (USD Million)
• Table 54 India neuromodulation devices market, by application, 2018 - 2030 (USD Million)
• Table 55 India neuromodulation devices market, by end-use, 2018 - 2030 (USD Million)
• Table 56 South Korea neuromodulation devices market, by Product, 2018 - 2030 (USD Million)
• Table 57 South Korea neuromodulation devices market, by application, 2018 - 2030 (USD Million)
• Table 58 South Korea neuromodulation devices market, by end-use, 2018 - 2030 (USD Million)
• Table 59 Australia neuromodulation devices market, by Product, 2018 - 2030 (USD Million)
• Table 60 Australia neuromodulation devices market, by application, 2018 - 2030 (USD Million)
• Table 61 Australia neuromodulation devices market, by end-use, 2018 - 2030 (USD Million)
• Table 62 Thailand neuromodulation devices market, by Product, 2018 - 2030 (USD Million)
• Table 63 Thailand neuromodulation devices market, by application, 2018 - 2030 (USD Million)
• Table 64 Thailand neuromodulation devices market, by end-use, 2018 - 2030 (USD Million)
• Table 65 Latin America neuromodulation devices market, by Product, 2018 - 2030 (USD Million)
• Table 66 Latin America neuromodulation devices market, by application, 2018 - 2030 (USD Million)
• Table 67 Latin America neuromodulation devices market, by end-use, 2018 - 2030 (USD Million)
• Table 68 Brazil neuromodulation devices market, by Product, 2018 - 2030 (USD Million)
• Table 69 Brazil neuromodulation devices market, by application, 2018 - 2030 (USD Million)
• Table 70 Brazil neuromodulation devices market, by end-use, 2018 - 2030 (USD Million)
• Table 71 Argentina neuromodulation devices market, by Product, 2018 - 2030 (USD Million)
• Table 72 Argentina neuromodulation devices market, by application, 2018 - 2030 (USD Million)
• Table 73 Argentina neuromodulation devices market, by end-use, 2018 - 2030 (USD Million)
• Table 74 MEA neuromodulation devices market, by region, 2018 - 2030 (USD Million)
• Table 75 MEA neuromodulation devices market, by Product, 2018 - 2030 (USD Million)
• Table 76 MEA neuromodulation devices market, by application, 2018 - 2030 (USD Million)
• Table 77 MEA neuromodulation devices market, by end-use, 2018 - 2030 (USD Million)
• Table 78 South Africa neuromodulation devices market, by Product, 2018 - 2030 (USD Million)
• Table 79 South Africa neuromodulation devices market, by application, 2018 - 2030 (USD Million)
• Table 80 South Africa neuromodulation devices market, by end-use, 2018 - 2030 (USD Million)
• Table 81 Saudi Arabia neuromodulation devices market, by Product, 2018 - 2030 (USD Million)
• Table 82 Saudi Arabia neuromodulation devices market, by application, 2018 - 2030 (USD Million)
• Table 83 Saudi Arabia neuromodulation devices market, by end-use, 2018 - 2030 (USD Million)
• Table 84 UAE neuromodulation devices market, by Product, 2018 - 2030 (USD Million)
• Table 85 UAE neuromodulation devices market, by application, 2018 - 2030 (USD Million)
• Table 86 UAE neuromodulation devices market, by end-use, 2018 - 2030 (USD Million)
• Table 87 Kuwait neuromodulation devices market, by Product, 2018 - 2030 (USD Million)
• Table 88 Kuwait neuromodulation devices market, by application, 2018 - 2030 (USD Million)
• Table 89 Kuwait neuromodulation devices market, by end-use, 2018 - 2030 (USD Million)

List of Figures

• Fig. 1 Neuromodulation devices market segmentation
• Fig. 2 Market research process
• Fig. 3 Information procurement
• Fig. 4 Primary research pattern
• Fig. 5 Value chain based sizing & forecasting
• Fig. 6 Market formulation & validation
• Fig. 7 Market snapshot (global and regional)
• Fig. 8 Product & end use segment snapshot
• Fig. 9 Application segment snapshot
• Fig. 10 Competitive landscape snapshot
• Fig. 11 Neurovascular devices market and neuromodulation devices market value
• Fig. 12 Porter's five forces analysis
• Fig. 13 PESTLE analysis
• Fig. 14 Neuromodulation devices market: Product outlook and key takeaways
• Fig. 15 Neuromodulation devices market: Product movement analysis
• Fig. 16 Spinal cord stimulation market estimates and forecast
• Fig. 17 Deep brain stimulation market estimates and forecast
• Fig. 18 Vagus nerve stimulation market estimates and forecast
• Fig. 19 Sacral nerve stimulation market estimates and forecast
• Fig. 20 Gastric electrical stimulation market estimates and forecast
• Fig. 21 Others market estimates and forecast
• Fig. 22 Neuromodulation devices market: Application outlook and key takeaways
• Fig. 23 Neuromodulation devices market: Application movement analysis
• Fig. 24 Parkinson's disease market estimates and forecast
• Fig. 25 Chronic pain market estimates and forecast
• Fig. 26 Migraine market estimates and forecast
• Fig. 27 Epilepsy market estimates and forecast
• Fig. 28 Tremor market estimates and forecast
• Fig. 29 Country-wise depression prevalence
• Fig. 30 Depression market estimates and forecast
• Fig. 31 Urinary & fecal incontinence market estimates and forecast
• Fig. 32 Others incontinence market estimates and forecast
• Fig. 33 Neuromodulation devices market: End-use outlook and key takeaways
• Fig. 34 Neuromodulation devices market: End-use movement analysis
• Fig. 35 Hospitals & ambulatory surgical centers market estimates and forecast
• Fig. 36 Clinics & physiotherapy centers market estimates and forecast
• Fig. 37 Others market estimates and forecast
• Fig. 38 Regional marketplace: Key takeaways
• Fig. 39 Regional marketplace: Key takeaways
• Fig. 40 North America neuromodulation devices market, 2018 - 2030 (USD Million)
• Fig. 41 Key country dynamics
• Fig. 42 U.S. neuromodulation devices market, 2018 - 2030 (USD Million)
• Fig. 43 Key country dynamics
• Fig. 44 Canada neuromodulation devices market, 2018 - 2030 (USD Million)
• Fig. 45 Key country dynamics
• Fig. 46 Mexico neuromodulation devices market, 2018 - 2030 (USD Million)
• Fig. 47 Europe neuromodulation devices market, 2018 - 2030 (USD Million)
• Fig. 48 Key country dynamics
• Fig. 49 UK neuromodulation devices market, 2018 - 2030 (USD Million)
• Fig. 50 Key country dynamics
• Fig. 51 Germany neuromodulation devices market, 2018 - 2030 (USD Million)
• Fig. 52 Key country dynamics
• Fig. 53 France neuromodulation devices market, 2018 - 2030 (USD Million)
• Fig. 54 Key country dynamics
• Fig. 55 Italy neuromodulation devices market, 2018 - 2030 (USD Million)
• Fig. 56 Key country dynamics
• Fig. 57 Spain neuromodulation devices market, 2018 - 2030 (USD Million)
• Fig. 58 Key country dynamics
• Fig. 59 Sweden neuromodulation devices market, 2018 - 2030 (USD Million)
• Fig. 60 Key country dynamics
• Fig. 61 Denmark neuromodulation devices market, 2018 - 2030 (USD Million)
• Fig. 62 Key country dynamics
• Fig. 63 Norway neuromodulation devices market, 2018 - 2030 (USD Million)
• Fig. 64 Asia Pacific neuromodulation devices market, 2018 - 2030 (USD Million)
• Fig. 65 Key country dynamics
• Fig. 66 Japan neuromodulation devices market, 2018 - 2030 (USD Million)
• Fig. 67 Key country dynamics
• Fig. 68 China neuromodulation devices market, 2018 - 2030 (USD Million)
• Fig. 69 Key country dynamics
• Fig. 70 India neuromodulation devices market, 2018 - 2030 (USD Million)
• Fig. 71 Key country dynamics
• Fig. 72 Australia neuromodulation devices market, 2018 - 2030 (USD Million)
• Fig. 73 Key country dynamics
• Fig. 74 New Zealand neuromodulation devices market, 2018 - 2030 (USD Million)
• Fig. 75 Key country dynamics
• Fig. 76 South Korea neuromodulation devices market, 2018 - 2030 (USD Million)
• Fig. 77 Key country dynamics
• Fig. 78 Thailand neuromodulation devices market, 2018 - 2030 (USD Million)
• Fig. 79 Latin America neuromodulation devices market, 2018 - 2030 (USD Million)
• Fig. 80 Key country dynamics
• Fig. 81 Brazil neuromodulation devices market, 2018 - 2030 (USD Million)
• Fig. 82 Key country dynamics
• Fig. 83 Argentina neuromodulation devices market, 2018 - 2030 (USD Million)
• Fig. 84 Middle East & Africa neuromodulation devices market, 2018 - 2030 (USD Million)
• Fig. 85 Key country dynamics
• Fig. 86 South Africa neuromodulation devices market, 2018 - 2030 (USD Million)
• Fig. 87 Key country dynamics
• Fig. 88 Saudi Arabia neuromodulation devices market, 2018 - 2030 (USD Million)
• Fig. 89 Key country dynamics
• Fig. 90 UAE neuromodulation devices market, 2018 - 2030 (USD Million)
• Fig. 91 Key country dynamics
• Fig. 92 Kuwait neuromodulation devices market, 2018 - 2030 (USD Million)
• Fig. 93 Key company categorization
• Fig. 94 Strategic framework

Neuromodulation Devices Market Growth & Trends:

The global neuromodulation devices market size is expected to reach USD 10.39 billion by 2030, registering a CAGR of 8.51% from 2025 to 2030, according to a new report by Grand View Research, Inc. The market's growth can be attributed to factors such as rising prevalence of neurological disorders, rising government support to R&D and development of advanced solutions with increased range of applications.

Significant funding from government and private agencies plays a crucial role in advancing the understanding of neurological disorders and improving treatment options. By allocating resources to research initiatives, governments actively facilitate groundbreaking discoveries, encourage technological innovations, and promote the development of more effective neuromodulation technologies. For instance, in August 2024, the Parkinson's Foundation announced an investment of nearly USD 3 million in 33 research grants aimed at advancing the understanding and treatment of Parkinson's disease (PD). This funding will support innovative research projects focusing on various aspects of PD, including its causes, progression, and potential therapies. The grants are part of the Foundation's commitment to fostering scientific advancements that can lead to improved patient outcomes. This financial backing is vital for shaping the treatment landscape for neurological disorders and driving positive changes in patient care.

Furthermore, the increasing accessibility of these advanced devices to patients and healthcare professionals has further increased their adoption. Expanding reimbursement is improving patient access to these advanced therapies. In recent years, healthcare systems have increasingly acknowledged the effectiveness of neuromodulation devices in managing chronic pain, neurological disorders, and various other medical conditions, which has led many healthcare payers to include these devices in their coverage policies. For instance, in February 2024, Nerivio Remote Electrical Neuromodulation (REN) wearable by Theranica became the first non-pharmacological migraine treatment to get commercial coverage in the U.S. from Highmark Inc. The wearable offers acute and preventive treatment options, demonstrating significant clinical benefits in reducing migraine symptoms. Thus, the growing acceptance of neuromodulation therapies among payers is driving market growth.

Neuromodulation Devices Market Report Highlights:

• Spinal cord stimulators held the largest market share of around 39.67% in 2024. Spinal cord stimulation devices are primarily used for patients without sufficient pain relief from non-surgical pain treatments.
• Parkinson's disease held the largest market share of around 26.90% in 2024. The rising prevalence of Parkinson's disease, coupled with the increasing acceptance of deep brain stimulation as an effective treatment option, is expected to drive segment growth.
• Hospitals & Ambulatory Surgery Centers (ASC) held the largest market share in 2024 and the same segments are expected to show fastest growth during the forecast period.
• North America neuromodulation devices market dominated with a share of 43.68% in 2024, owing to increase in the prevalence of various neurological disorders, such as Alzheimer's disease, Parkinson's disease, and epilepsy, and a rise in the demand for minimally invasive neurological procedures.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Segment Definitions
  • 1.2.1. Product
  • 1.2.2. Application
  • 1.2.3. End Use
  • 1.2.4. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Regional outlook
• 2.4. Competitive Insights

Chapter 3. Neuromodulation Devices Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Government funding for research and development
    • 3.2.1.2. Technological advancements in neuromodulation devices
    • 3.2.1.3. Increasing prevalence of neurological disorders
    • 3.2.1.4. Growing reimbursement coverage
    • 3.2.1.5. Expanding applications
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. Complex regulatory framework
    • 3.2.2.2. Surgery-associated risk
• 3.3. Neuromodulation Devices Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Bargaining power of suppliers
    • 3.3.1.2. Bargaining power of buyers
    • 3.3.1.3. Threat of substitutes
    • 3.3.1.4. Threat of new entrants
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Economic landscape
    • 3.3.2.3. Social landscape
    • 3.3.2.4. Technological landscape
    • 3.3.2.5. Environmental landscape
    • 3.3.2.6. Legal landscape

Chapter 4. Neuromodulation Devices Market - Segment Analysis, by Product, 2018 - 2030 (USD Million)

• 4.1. Neuromodulation Devices Market: Product Outlook and Key Takeaways
• 4.2. Neuromodulation Devices Market: Product Movement Analysis
• 4.3. Neuromodulation Devices Market Estimates & Forecast, by Product (USD Million)
• 4.4. Spinal Cord Stimulators
  • 4.4.1. Spinal Cord Stimulators Market, 2018 - 2030 (USD Million)
• 4.5. Deep Brain Stimulators
  • 4.5.1. Deep Brain Stimulators Market, 2018 - 2030 (USD Million)
• 4.6. Sacral Nerve Stimulators
  • 4.6.1. Sacral Nerve Stimulators Market, 2018 - 2030 (USD Million)
• 4.7. Vagus Nerve Stimulators
  • 4.7.1. Vagus Nerve Stimulators Market, 2018 - 2030 (USD Million)
• 4.8. Gastric Electrical Stimulation
  • 4.8.1. Gastric Electrical Stimulation Market, 2018 - 2030 (USD Million)
• 4.9. Others
  • 4.9.1. Others Market, 2018 - 2030 (USD Million)

Chapter 5. Neuromodulation Devices Market - Segment Analysis, by Application, 2018 - 2030 (USD Million)

• 5.1. Neuromodulation Devices Market: Application Outlook and Key Takeaways
• 5.2. Neuromodulation Devices Market: Application Movement Analysis
• 5.3. Neuromodulation Devices Market Estimates & Forecast, by Application (USD Million)
• 5.4. Parkinson's Disease
  • 5.4.1. Parkinson's Disease Market, 2018 - 2030 (USD Million)
• 5.5. Chronic Pain
  • 5.5.1. Chronic Pain Market, 2018 - 2030 (USD Million)
• 5.6. Epilepsy
  • 5.6.1. Epilepsy Market, 2018 - 2030 (USD Million)
• 5.7. Migraine
  • 5.7.1. Migraine Market, 2018 - 2030 (USD Million)
• 5.8. Urinary & Faecal Incontinence
  • 5.8.1. Urinary & Faecal Incontinence Market, 2018 - 2030 (USD Million)
• 5.9. Tremor
  • 5.9.1. Tremor Market, 2018 - 2030 (USD Million)
• 5.10. Depression
  • 5.10.1. Depression Market, 2018 - 2030 (USD Million)
• 5.11. Others
  • 5.11.1. Others Market, 2018 - 2030 (USD Million)

Chapter 6. Neuromodulation Devices Market - Segment Analysis, by End Use, 2018 - 2030 (USD Million)

• 6.1. Neuromodulation Devices Market: End Use Outlook and Key Takeaways
• 6.2. Neuromodulation Devices Market: End Use Movement Analysis
• 6.3. Neuromodulation Devices Market Estimates & Forecast, by End Use (USD Million)
• 6.4. Hospitals & Ambulatory Surgery Centers (ASC)
  • 6.4.1. Hospitals & Ambulatory Surgery Centers (ASC) Market, 2018 - 2030 (USD Million)
• 6.5. Clinics & Physiotherapy Centers
  • 6.5.1. Clinics & Physiotherapy Centers Market, 2018 - 2030 (USD Million)
• 6.6. Others
  • 6.6.1. Others Market, 2018 - 2030 (USD Million

Chapter 7. Neuromodulation Devices Market: Regional Estimates & Trend Analysis

• 7.1. Regional Dashboard
• 7.2. Market Size & Forecasts Trend Analysis, 2018 to 2030:
• 7.3. North America
  • 7.3.1. U.S.
    • 7.3.1.1. Key country dynamics
    • 7.3.1.2. Regulatory framework/ reimbursement structure
    • 7.3.1.3. Competitive scenario
    • 7.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.3.2. Canada
    • 7.3.2.1. Key country dynamics
    • 7.3.2.2. Regulatory framework/ reimbursement structure
    • 7.3.2.3. Competitive scenario
    • 7.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.3.3. Mexico
    • 7.3.3.1. Key country dynamics
    • 7.3.3.2. Regulatory framework/ reimbursement structure
    • 7.3.3.3. Competitive scenario
    • 7.3.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
• 7.4. Europe
  • 7.4.1. UK
    • 7.4.1.1. Key country dynamics
    • 7.4.1.2. Regulatory framework/ reimbursement structure
    • 7.4.1.3. Competitive scenario
    • 7.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.2. Germany
    • 7.4.2.1. Key country dynamics
    • 7.4.2.2. Regulatory framework/ reimbursement structure
    • 7.4.2.3. Competitive scenario
    • 7.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.3. France
    • 7.4.3.1. Key country dynamics
    • 7.4.3.2. Regulatory framework/ reimbursement structure
    • 7.4.3.3. Competitive scenario
    • 7.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.4. Italy
    • 7.4.4.1. Key country dynamics
    • 7.4.4.2. Regulatory framework/ reimbursement structure
    • 7.4.4.3. Competitive scenario
    • 7.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.5. Spain
    • 7.4.5.1. Key country dynamics
    • 7.4.5.2. Regulatory framework/ reimbursement structure
    • 7.4.5.3. Competitive scenario
    • 7.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.6. Norway
    • 7.4.6.1. Key country dynamics
    • 7.4.6.2. Regulatory framework/ reimbursement structure
    • 7.4.6.3. Competitive scenario
    • 7.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.7. Sweden
    • 7.4.7.1. Key country dynamics
    • 7.4.7.2. Regulatory framework/ reimbursement structure
    • 7.4.7.3. Competitive scenario
    • 7.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.8. Denmark
    • 7.4.8.1. Key country dynamics
    • 7.4.8.2. Regulatory framework/ reimbursement structure
    • 7.4.8.3. Competitive scenario
    • 7.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
• 7.5. Asia Pacific
  • 7.5.1. Japan
    • 7.5.1.1. Key country dynamics
    • 7.5.1.2. Regulatory framework/ reimbursement structure
    • 7.5.1.3. Competitive scenario
    • 7.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.2. China
    • 7.5.2.1. Key country dynamics
    • 7.5.2.2. Regulatory framework/ reimbursement structure
    • 7.5.2.3. Competitive scenario
    • 7.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.3. India
    • 7.5.3.1. Key country dynamics
    • 7.5.3.2. Regulatory framework/ reimbursement structure
    • 7.5.3.3. Competitive scenario
    • 7.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.4. Australia
    • 7.5.4.1. Key country dynamics
    • 7.5.4.2. Regulatory framework/ reimbursement structure
    • 7.5.4.3. Competitive scenario
    • 7.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.5. South Korea
    • 7.5.5.1. Key country dynamics
    • 7.5.5.2. Regulatory framework/ reimbursement structure
    • 7.5.5.3. Competitive scenario
    • 7.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.6. Thailand
    • 7.5.6.1. Key country dynamics
    • 7.5.6.2. Regulatory framework/ reimbursement structure
    • 7.5.6.3. Competitive scenario
    • 7.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
• 7.6. Latin America
  • 7.6.1. Brazil
    • 7.6.1.1. Key country dynamics
    • 7.6.1.2. Regulatory framework/ reimbursement structure
    • 7.6.1.3. Competitive scenario
    • 7.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.2. Argentina
    • 7.6.2.1. Key country dynamics
    • 7.6.2.2. Regulatory framework/ reimbursement structure
    • 7.6.2.3. Competitive scenario
    • 7.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
• 7.7. MEA
  • 7.7.1. South Africa
    • 7.7.1.1. Key country dynamics
    • 7.7.1.2. Regulatory framework/ reimbursement structure
    • 7.7.1.3. Competitive scenario
    • 7.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.2. Saudi Arabia
    • 7.7.2.1. Key country dynamics
    • 7.7.2.2. Regulatory framework/ reimbursement structure
    • 7.7.2.3. Competitive scenario
    • 7.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.3. UAE
    • 7.7.3.1. Key country dynamics
    • 7.7.3.2. Regulatory framework/ reimbursement structure
    • 7.7.3.3. Competitive scenario
    • 7.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.4. Kuwait
    • 7.7.4.1. Key country dynamics
    • 7.7.4.2. Regulatory framework/ reimbursement structure
    • 7.7.4.3. Competitive scenario
    • 7.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Market Participant Categorization
• 8.2. Recent Developments & Impact Analysis by Key Market Participants
• 8.3. Company Market Share Analysis, 2024
• 8.4. Key Company Profiles
  • 8.4.1. Abbott
    • 8.4.1.1. Company overview
    • 8.4.1.2. Financial performance
    • 8.4.1.3. Product benchmarking
    • 8.4.1.4. Strategic initiatives
  • 8.4.2. Medtronic
    • 8.4.2.1. Company overview
    • 8.4.2.2. Financial performance
    • 8.4.2.3. Product benchmarking
    • 8.4.2.4. Strategic initiatives
  • 8.4.3. Boston Scientific Corporation
    • 8.4.3.1. Company overview
    • 8.4.3.2. Financial performance
    • 8.4.3.3. Product benchmarking
    • 8.4.3.4. Strategic initiatives
  • 8.4.4. Nexstim
    • 8.4.4.1. Company overview
    • 8.4.4.2. Financial performance
    • 8.4.4.3. Product benchmarking
    • 8.4.4.4. Strategic initiatives
  • 8.4.5. LivaNova PLC
    • 8.4.5.1. Company overview
    • 8.4.5.2. Financial performance
    • 8.4.5.3. Product benchmarking
    • 8.4.5.4. Strategic initiatives
  • 8.4.6. Neuropace Inc.
    • 8.4.6.1. Company overview
    • 8.4.6.2. Financial performance
    • 8.4.6.3. Product benchmarking
    • 8.4.6.4. Strategic initiatives
  • 8.4.7. Nevro Corporation
    • 8.4.7.1. Company overview
    • 8.4.7.2. Financial performance
    • 8.4.7.3. Product benchmarking
    • 8.4.7.4. Strategic initiatives
  • 8.4.8. electroCore, Inc.
    • 8.4.8.1. Company overview
    • 8.4.8.2. Financial performance
    • 8.4.8.3. Product benchmarking
    • 8.4.8.4. Strategic initiatives
  • 8.4.9. Axonics, Inc.
    • 8.4.9.1. Company overview
    • 8.4.9.2. Financial performance
    • 8.4.9.3. Product benchmarking
    • 8.4.9.4. Strategic initiatives
  • 8.4.10. Laborie
    • 8.4.10.1. Company overview
    • 8.4.10.2. Financial performance
    • 8.4.10.3. Product benchmarking
    • 8.4.10.4. Strategic initiatives